Lytix Biopharma Employee Directory
Biotechnology ResearchOslo, Norway11-50 Employees
Lytix Biopharma is a clinical-stage biotechnology company based in Oslo, Norway, developing a new class of peptide-based oncolytic molecules for cancer therapy. These agents aim to destroy tumors locally and trigger a durable anti-tumor immune response by promoting rapid immunogenic tumor cell death and subsequent antigen presentation, potentially improving responses to checkpoint inhibitors. The company engages with a global advisory network, including Nobel Laureate Jim Allison, to guide translational development. Its pipeline includes VP-315 (ruxotemitide) for neoadjuvant melanoma, with broader potential in superficial tumors such as basal cell carcinoma and Merkel cell carcinoma. Verrica Pharmaceuticals is a partner that has reported positive Phase 2 data in basal cell carcinoma, reflecting external validation of the platform, while Lytix is advancing LTX 401 for deep-seated tumors based on preclinical data in liver cancer models.
1-888-653-2347 
support@leadiq.com 
